Family members and friends have begun identifying many of the 16 American service members who died on Monday when their plane crashed in rural Mississippi.
NYS Entity Status
NYS Filing Date
JUNE 12, 2014
NYS DOS ID#
NYS Entity Type
DOMESTIC BUSINESS CORPORATION
2014 - 103 CAMERON ST CORP.
AROUND THE WEB
- Marine Corps Plane Crash: The Victims
By THE NEW YORK TIMES - Thursday Jul 13, 2017
- Could the Rockaways Survive Another Sandy?
By LUIS FERRÉ-SADURNÍ - Thursday Jul 13, 2017
Residents are bracing for the worst, wondering whether measures taken so far are enough to keep devastation of the Queens community at bay.
- Time capsule found in Confederate monument
By Yaron Steinbuch - Friday Jun 30, 2017
Workers removing a controversial Confederate monument in a St. Louis park made an “Indiana Jones”-like discovery — a time capsule hidden inside the 103-year-old granite landmark. Mark Trout, director of the Missouri Civil War Museum, told Fox 2 St. Louis that workers dismantling the last pieces of the 38-foot-tall monument popped loose the waterlogged, sealed...
- Patty Jenkins Corrects James Cameron’s ‘Misguided’ Comments About ‘Wonder Woman’
By Josh Kurp - Friday Aug 25, 2017
James Cameron, take a step backwards.
- FDA advisers review data on potential 1st US gene therapy
By LINDA A. JOHNSON, AP Medical Writer - Wednesday Jul 12, 2017
Cancer experts who advise government regulators are reviewing what could be the first gene therapy approved in the U.S.The Food and Drug Administration panel is holding a hearing Wednesday to discuss the treatment developed by the University of Pennsylvania and Novartis Corp. The drugmaker is seeking approval to use the one-time treatment for children and young adults with advanced leukemia.
- Novel leukemia treatment could be 1st US gene therapy
By Associated Press - Thursday Jul 13, 2017
A treatment for a common childhood blood cancer could become the first gene therapy available in the U.S. A Food and Drug Administration advisory panel voted 10-0 on Wednesday in favor of the leukemia treatment developed by the University of Pennsylvania and Novartis Corp. The FDA usually follows recommendations from its expert panels, but isn’t...